+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Spatial Genomics Market by Type (Genomics, Transcriptomics) Technology (Sequencing, Imaging) Application (Oncology, Neurology) Offering (Consumables, Instrument, Software) End User (Pharmaceutical & Biotechnology, CRO) - Forecast to 2031

  • PDF Icon

    Report

  • 198 Pages
  • January 2024
  • Region: Global
  • Meticulous Market Research Pvt. Ltd.
  • ID: 5923483
UP TO OFF until Jan 10th 2025
The global spatial genomics & transcriptomics market is expected to reach $3.23 billion by 2031 at a CAGR of 27.8% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the spatial genomics market is driven by the increasing applications of spatial genomics in drug discovery & development, the growing use of spatial genomics in cancer research, advancements in Next-generation Sequencing (NGS), the increasing use of spatial genomics in biomarker detection, and the rising prevalence of cancer. However, the lack of standardized approaches in genomics and concerns over the security & privacy of genomic data restrain the growth of this market.

Furthermore, the rising adoption of personalized medicines and gene therapies and increasing investments in spatial genomics are expected to generate growth opportunities for the players operating in this market. However, complexities in data analysis and slow technology adoption are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020-2024). The key players operating in the global spatial genomics & transcriptomics market are NanoString Technologies, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Illumina, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Akoya Biosciences, Inc. (U.S.), Revvity, Inc. (U.S.), S2 Genomics, Inc. (U.S.), Cantata Bio (U.S.), Vizgen Inc. (U.S.), Biospyder Technologies Inc. (U.S.), and Resolve Biosciences GmbH (Germany).

Among all the offerings studied in this report, the instruments segment is projected to register the highest CAGR during the forecast period. The use of instruments to profile the tumor microenvironment and the adoption of spatial transcriptomics in academics and research laboratories for drug and translational research are positively impacting the demand for instruments used in spatial genomics. Additionally, product launches by key market players support market growth. For instance, in December 2022, 10X Genomics, Inc. (U.S.) launched a Xenium Analyzer for subcellular in situ profiling.

Among all the types studied in this report, in 2024, the transcriptomics segment is expected to account for the largest share of the spatial genomics & transcriptomics market. The largest share of the segment is attributed to the increasing use of spatial transcriptomics to provide a complete roadmap of transcriptional activity within whole tissue sections required in translational research. Additionally, increasing acceptance of spatial transcriptomic technology for the identification of cellular components is driving the market growth.

Among all the technologies studied in this report, the sequencing-based segment is projected to register the highest CAGR during the forecast period. The growth of the segment is attributed to the NGS platforms offering superior sequencing capacity at substantially reduced costs, owing to which the use of NGS has increased in genomic studies to produce massive genomic sequencing data. Additionally, high throughput, low cost, individual characterization of cells, and analysis of multiple targets drive the market growth.

Among all the applications studied in this report, in 2024, the oncology segment is expected to account for the largest share of the spatial genomics & transcriptomics market. Increasing applications of spatial genomics & transcriptomics in tumor biology, such as the study of tumor heterogeneity, detecting the presence of infiltrating immune cells, and insights into tumor microenvironment, are contributing to the largest share of the segment. Additionally, the product launches by key market players are supporting the largest market share. For instance, in April 2023, Akoya Biosciences (U.S.) launched PhenoCode Discovery Panels for the advancements in cancer research.

Among all the end users studied in this report, the pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The growth is attributed to the increasing research & development by pharmaceutical & biotechnology companies, the rising utilization of spatial genomics assays for research processes, and an increasing number of biotechnology companies. Moreover, the rising incidence of chronic diseases has accelerated the need to expedite drug development processes, further propelling the adoption of spatial genomics among pharmaceutical companies.

An in-depth analysis of the geographical scenario of the global spatial genomics & transcriptomics market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of the spatial genomics & transcriptomics market. North America holds the predominant share in the region, largely due to its multitude of esteemed research institutions, universities, and organizations committed to genomics research. The region has played a pivotal role in advancing cancer genomics, driven by substantial investments in pharmaceutical research and development and the significant presence of key industry players. For instance, R&D spending by pharmaceutical companies in Canada for drug discovery has increased, driving the demand for spatial genomics. For instance, in 2020, total R&D expenditure in Canada’s pharmaceutical sector was estimated at between USD 1.8 billion and USD 2.4 billion, compared to USD 1.6 billion and USD 2.2 billion in 2019

Scope of the Report:

Spatial Genomics Market Assessment, by Offering

  • Instruments
  • Consumables
  • Software & Services

Spatial Genomics Market Assessment, by Type

  • Transcriptomics
  • Genomics

Spatial Genomics Market Assessment, by Technology

  • Imaging Based
  • Sequencing Based

Spatial Genomics Market Assessment, by Application

  • Oncology
  • Neurology
  • Other Applications
Note: Other applications consist of infectious diseases and immunology.

Spatial Genomics Market Assessment, by End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Other End Users
Note: Other end users include academic institutes & research centers and agriculture companies.

Spatial Genomics Market Assessment, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of Asia-Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Table of Contents

1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.1.1. Increasing Applications of Spatial Genomics in Drug Discovery & Development Driving Market Growth
4.2.1.2. Lack of Standardization and Concerns Over the Privacy of Genomic Data Limiting the Adoption of Spatial Genomics Products
4.2.1.3. Rising Adoption of Personalized Medicines Generating Growth Opportunities for Market Players
4.2.1.4. Complexities in Data Analysis to Remain a Major Challenge Impacting Market Growth
4.2.2. Factor Analysis
4.3. Technology Trends
4.3.1. Integration of Artificial Intelligence (AI) in Spatial Genomics
4.3.2. Multiplexed Spatial Genomics
4.4. Investment and Funding Scenario
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
5. Spatial Genomics & Transcriptomics Market Assessment - by Offering
5.1. Overview
5.2. Instruments
5.3. Consumables
5.4. Software & Services
6. Spatial Genomics & Transcriptomics Market Assessment - by Type
6.1. Overview
6.2. Transcriptomics
6.3. Genomics
7. Spatial Genomics & Transcriptomics Market Assessment - by Technology
7.1. Overview
7.2. Imaging Based
7.3. Sequencing Based
8. Spatial Genomics & Transcriptomics Market Assessment - by Application
8.1. Overview
8.2. Oncology
8.3. Neurology
8.4. Other Applications
9. Spatial Genomics & Transcriptomics Market Assessment - by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Contract Research Organizations
9.4. Other End Users
10. Spatial Genomics & Transcriptomics Market Assessment - by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.6. Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis
11.5.1. 10X Genomics, Inc. (U.S.)
11.5.2. NanoString Technologies, Inc. (U.S.)
11.5.3. Akoya Biosciences, Inc. (U.S.)
12. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
12.1. 10X Genomics, Inc.
12.2. NanoString Technologies, Inc.
12.3. Akoya Biosciences, Inc.
12.4. Illumina, Inc.
12.5. Oxford Nanopore Technologies Plc
12.6. Revvity, Inc.
12.7. S2 Genomics, Inc.
12.8. Cantata Bio
12.9. Vizgen Inc.
12.10. Biospyder Technologies Inc.
12.11 Resolve Biosciences GmbH
(Note: SWOT Analysis of Top 5 Companies is Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Estimated Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 2 Recent Investments and Funding in The Spatial Genomics & Transcriptomics Market
Table 3 Spatial Genomics & Transcriptomics Instruments: Pricing (USD/Unit)
Table 4 Spatial Genomics & Transcriptomics Consumables: Pricing (USD/Unit)
Table 5 Global Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 6 Key Companies Offering Instruments
Table 7 Global Spatial Genomics & Transcriptomics Market for Instruments, by Country/Region, 2022-2031 (USD Million)
Table 8 Key Companies Offering Consumables
Table 9 Global Spatial Genomics & Transcriptomics Market for Consumables, by Country/Region, 2022-2031 (USD Million)
Table 10 Key Companies Offering Software
Table 11 Global Spatial Genomics & Transcriptomics Market for Software & Services, by Country/Region, 2022-2031 (USD Million)
Table 12 Global Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 13 Global Spatial Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 14 Spatial Genomics: Key Application Areas
Table 15 Global Spatial Genomics Market, by Country/Region, 2022-2031 (USD Million)
Table 16 Global Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 17 Global Imaging Based Spatial Genomics & Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 18 Global Sequencing Based Spatial Genomics & Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 19 Global Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 20 Global Spatial Genomics & Transcriptomics Market for Oncology, by Country/Region, 2022-2031 (USD Million)
Table 21 Global Spatial Genomics & Transcriptomics Market for Neurology, by Country/Region, 2022-2031 (USD Million)
Table 22 Global Spatial Genomics & Transcriptomics Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
Table 23 Global Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 24 Global Spatial Genomics & Transcriptomics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
Table 25 Global Spatial Genomics & Transcriptomics Market for Contract Research Organizations, by Country/Region, 2022-2031 (USD Million)
Table 26 Global Spatial Genomics & Transcriptomics Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
Table 27 Global Spatial Genomics & Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 28 North America: Spatial Genomics & Transcriptomics Market, by Country, 2022-2031 (USD Million)
Table 29 North America: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 30 North America: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 31 North America: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 32 North America: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 33 North America: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 34 U.S.: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 35 U.S.: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 36 U.S.: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 37 U.S.: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 38 U.S.: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 39 Canada: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 40 Canada: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 41 Canada: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 42 Canada: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 43 Canada: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 44 Europe: Spatial Genomics & Transcriptomics Market, by Country/Region, 2022-2031 (USD Million)
Table 45 Europe: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 46 Europe: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 47 Europe: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 48 Europe: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 49 Europe: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 50 Germany: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 51 Germany: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 52 Germany: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 53 Germany: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 54 Germany: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 55 France: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 56 France: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 57 France: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 58 France: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 59 France: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 60 U.K.: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 61 U.K.: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 62 U.K.: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 63 U.K.: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 64 U.K.: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 65 Italy: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 66 Italy: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 67 Italy: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 68 Italy: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 69 Italy: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 70 Spain: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 71 Spain: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 72 Spain: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 73 Spain: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 74 Spain: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 75 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Offering, 2022-2031 (USD Million)
Table 76 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Type, 2022-2031 (USD Million)
Table 77 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Technology, 2022-2031 (USD Million)
Table 78 Rest of Europe: Spatial Genomics & Transcriptomics Market, by Application, 2022-2031 (USD Million)
Table 79 Rest of Europe: Spatial Genomics & Transcriptomics Market, by End User, 2022-2031 (USD Million)
Table 80 Asia-Pacific: Spatial Genomics Market, by Country/Region, 2022-2031 (USD Million)
Table 81 Asia-Pacific: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 82 Asia-Pacific: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 83 Asia-Pacific: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 84 Asia-Pacific: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 85 Asia-Pacific: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 86 China: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 87 China: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 88 China: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 89 China: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 90 China: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 91 Japan: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 92 Japan: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 93 Japan: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 94 Japan: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 95 Japan: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 96 India: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 97 India: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 98 India: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 99 India: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 100 India: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 101 Rest of Asia-Pacific: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 102 Rest of Asia-Pacific: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 103 Rest of Asia-Pacific: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 104 Rest of Asia-Pacific: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 105 Rest of Asia-Pacific: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 106 Latin America: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 107 Latin America: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 108 Latin America: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 109 Latin America: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 110 Latin America: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 111 Middle East & Africa: Spatial Genomics Market, by Offering, 2022-2031 (USD Million)
Table 112 Middle East & Africa: Spatial Genomics Market, by Type, 2022-2031 (USD Million)
Table 113 Middle East & Africa: Spatial Genomics Market, by Technology, 2022-2031 (USD Million)
Table 114 Middle East & Africa: Spatial Genomics Market, by Application, 2022-2031 (USD Million)
Table 115 Middle East & Africa: Spatial Genomics Market, by End User, 2022-2031 (USD Million)
Table 116 Recent Developments, by Company, 2020-2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Spatial Genomics & Transcriptomics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 8 Global Spatial Genomics & Transcriptomics Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 9 Global Spatial Genomics & Transcriptomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 10 Global Spatial Genomics & Transcriptomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 11 Global Spatial Genomics & Transcriptomics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 12 Spatial Genomics & Transcriptomics Market, by Geography
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Global Pharmaceutical R&D Expenditure, 2012-2026 (USD Billion)
Figure 15 Estimated Number of New Cancer Cases, by Region, 2020 Vs. 2030 (In Thousand)
Figure 16 Global Increase in The Number of Personalized Medicine Approvals, 2008-2020
Figure 17 Porter’s Five Forces Analysis
Figure 18 Global Spatial Genomics & Transcriptomics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 19 Global Spatial Genomics & Transcriptomics Market, by Type, 2024 Vs. 2031 (USD Million)
Figure 20 Global Spatial Genomics & Transcriptomics Market, by Technology, 2024 Vs. 2031 (USD Million)
Figure 21 Imaging Based Methods: Workflow
Figure 22 Sequencing Based Methods: Workflow
Figure 23 Global Spatial Genomics & Transcriptomics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 24 Global Spatial Genomics & Transcriptomics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 25 Global Pharmaceutical R&D Spending, 2012-2026 (USD Billion)
Figure 26 Global Spatial Genomics & Transcriptomics Market, by Region, 2024 Vs. 2031 (USD Million)
Figure 27 North America: Spatial Genomics & Transcriptomics Market Snapshot
Figure 28 U.S.: Pharmaceutical R&D Expenditures, 2014-2021 (USD Billion)
Figure 29 Europe: Pharmaceutical R&D Expenditures, 2000-2021 (USD Million)
Figure 30 Europe: Spatial Genomics & Transcriptomics Market Snapshot
Figure 31 Roe: Countries Pharmaceutical R&D Expenditures, 2021 (USD Million)
Figure 32 Asia-Pacific: Spatial Genomics Market Snapshot
Figure 33 Key Growth Strategies Adopted by Leading Players, 2020-2023
Figure 34 Spatial Genomics & Transcriptomics Market: Competitive Benchmarking (Based on Offering)
Figure 35 Spatial Genomics & Transcriptomics Market: Competitive Benchmarking (Based on Geography)
Figure 36 Competitive Dashboard: Spatial Genomics & Transcriptomics Market
Figure 37 Global Spatial Genomics & Transcriptomics Market Share Analysis, by Key Players (2023)
Figure 38 10x Genomics, Inc.: Financial Overview (2022)
Figure 39 NanoString Technologies, Inc.: Financial Overview (2022)
Figure 40 Akoya Biosciences, Inc.: Financial Overview (2022)
Figure 41 Illumina, Inc.: Financial Overview (2022)
Figure 42 Oxford Nanopore Technologies Plc.: Financial Overview (2022)
Figure 43 PerkinElmer, Inc: Financial Overview (2022)

Companies Mentioned

  • NanoString Technologies Inc. (U.S.)
  • 10X Genomics Inc. (U.S.)
  • Illumina Inc. (U.S.)
  • Oxford Nanopore Technologies Plc. (U.K.)
  • Akoya Biosciences Inc. (U.S.)
  • Revvity Inc. (U.S.)
  • S2 Genomics Inc. (U.S.)
  • Cantata Bio (U.S.)
  • Vizgen Inc. (U.S.)
  • Biospyder Technologies Inc. (U.S.)
  • Resolve Biosciences GmbH (Germany)